234 related articles for article (PubMed ID: 21438190)
1. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
[No Abstract] [Full Text] [Related]
2. Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies.
Craddock C
Cytotherapy; 2011 May; 13(5):516-7. PubMed ID: 21375421
[No Abstract] [Full Text] [Related]
3. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
[TBL] [Abstract][Full Text] [Related]
4. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
Alencar C; Abramowtiz M; Parekh S; Braunshweig I; Jacobson M; Silverman L; Verma A
Am J Hematol; 2009 Oct; 84(10):688-9. PubMed ID: 19722261
[No Abstract] [Full Text] [Related]
5. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
6. Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies.
Kantarjian HM; Cortes JE; Rowe JM; Kurzrock R
Semin Hematol; 2002 Jul; 39(3 Suppl 2):36-8. PubMed ID: 12214292
[TBL] [Abstract][Full Text] [Related]
7. [Epigenetics in hematological disorders].
Furukawa Y
Rinsho Ketsueki; 2008 Oct; 49(10):1472-82. PubMed ID: 18833931
[No Abstract] [Full Text] [Related]
8. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Stahl M; Gore SD; Vey N; Prebet T
Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
[TBL] [Abstract][Full Text] [Related]
9. [Epigenetic therapy in myelodysplastic syndromes].
Maki K; Mitani K
Rinsho Ketsueki; 2011 Jul; 52(7):438-46. PubMed ID: 21821974
[No Abstract] [Full Text] [Related]
10. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
11. Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. Introduction.
Baylin SB; Mufti GJ
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S1-3. PubMed ID: 16341235
[No Abstract] [Full Text] [Related]
12. More is better: combination therapies for myelodysplastic syndromes.
Ornstein MC; Mukherjee S; Sekeres MA
Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
[TBL] [Abstract][Full Text] [Related]
13. Improving the outlook for myelodysplastic syndrome.
Brower V
J Natl Cancer Inst; 2012 Aug; 104(16):1204-6. PubMed ID: 22899627
[No Abstract] [Full Text] [Related]
14. Molecular cytogenetic aspects of hematological malignancies: clinical implications.
Chen Z; Sandberg AA
Am J Med Genet; 2002 Oct; 115(3):130-41. PubMed ID: 12407693
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
Yang AS; Doshi KD; Choi SW; Mason JB; Mannari RK; Gharybian V; Luna R; Rashid A; Shen L; Estecio MR; Kantarjian HM; Garcia-Manero G; Issa JP
Cancer Res; 2006 May; 66(10):5495-503. PubMed ID: 16707479
[TBL] [Abstract][Full Text] [Related]
16. The use of hypomethylating agents in the treatment of hematologic malignancies.
Kihslinger JE; Godley LA
Leuk Lymphoma; 2007 Sep; 48(9):1676-95. PubMed ID: 17786703
[TBL] [Abstract][Full Text] [Related]
17. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
Lübbert M; Kuendgen A
Cancer; 2015 Feb; 121(4):498-501. PubMed ID: 25336205
[No Abstract] [Full Text] [Related]
18. Inhibitors of DNA methylation: beyond myelodysplastic syndromes.
Fenaux P
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S36-44. PubMed ID: 16341239
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Leone G; Voso MT; Teofili L; Lübbert M
Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
[TBL] [Abstract][Full Text] [Related]
20. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
[No Abstract] [Full Text] [Related]
[Next] [New Search]
